Different Suction Techniques For Endoscopic Ultrasound-Guided Fine-Needle Biopsy In Pancreatic Solid Lesions

February 22, 2019 updated by: Roberto Di Mitri, ARNAS Civico Di Cristina Benfratelli Hospital

Stylet Slow-Pull Technique Compared To Standard Suction For Endoscopic Ultrasound-Guided Fine-Needle Biopsy In Pancreatic Solid Lesions: Data From A National Multicenter Randomized Trial

Ultrasound-guided fine-needle aspiration represents the gold-standard for the pathological diagnosis of solid pancreatic lesions. New needles design allowed to obtain samples suitable for histological evaluation (endoscopic ultrasound-guided fine needle biopsy). the aim was to compare two different techniques during ultrasound-guided fine needle biopsy, for diagnosis of suspect pancreatic solid lesions.

Study Overview

Detailed Description

Materials and methods This is a prospective, randomized, multicenter study comparing the slow-pull technique with the standard suction technique during Ultrasound-guided fine-needle biopsy in patients with pancreatic solid lesions. The study involved three referral centers for pancreatico-biliary diseases: the Gastroenterology and Endoscopy Unit. ARNAS Civico-Di Cristina-Benfratelli Hospital, Palermo, Italy; the Gastroenterology and Endoscopy Unit. Marche Polytechnic University, Ospedale A. Murri, Fermo, Italy; the Gastroenterology Unit. AUSL Bologna, Bellaria-Maggiore, Bologna, Italy. The protocol was approved by the institutional medical ethical committee at each participating institution and written informed consent was obtained from all patients for participation in the study. All consecutive patients with a newly diagnosed pancreatic solid lesions suitable for endoscopic ultrasound-guided tissue acquisition were considered for enrollment. Written informed consent was obtained from all patients before the procedure. All the endoscopic ultrasound procedures were carried out by a skilled endosonographer with the patients under conscious sedation or deep sedation according to the anesthesiological guidelines approved in each participating center. All Ultrasound-guided fine-needle biopsy were done using a 20 Gauge needle (EchoTip ProCore 20G with ReCoil Stylet™, Cook Medical, Bloomington, IN, USA). The ReCoil Stylet´s has an automatic recoiling capability designed to help users to manage more easily the stylet, thus minimising the risk of contamination. Before puncturing, color doppler examination was performed to exclude the presence of interposing vessels. The needle tip was sharpened by withdrawing the stylet of approximately 2 mm, and then it was advanced into the lesion under real-time endoscopic ultrasound guidance. In patients randomized to the stylet slow-pull techniques, 15 to-and-fro movements within the lesion were performed while gently pulling the needle stylet slowly and continuously upwards. In patients randomized to the standard suction technique, 15 to-and-fro movements within the lesion were performed using a 10-mL suction syringe. In both sampling procedures the fanning technique was used to maximized sample acquisition. Tissue samples were expelled onto slides by reinserting the stylet and the visible core was physically lifted off the slides placing it into a formalin vial for histological evaluation. For the macroscopic adequacy, the endosonographer evaluated for the presence of a visible core defined as a worm-like material whitish/yellowish or red, not including fluid-like specimens in the formalin vial, which was judged to be adequate to perform a pathological analysis. The pathologists were "blinded" on which group the vials received were belonging to.

Randomization was performed using random sequences generated by a computer and then closed in consecutive numbered envelopes.

The degree of blood contamination of the specimen was based on the pathologist evaluation of the formalin fixed and paraffin embedded tissue samples and defined as significant when a large amount of blood cells made pathological diagnosis difficult to be made. On the other hand, blood contamination of the specimen was defined as not significant when no or only few blood cells were present without any influence on the pathological diagnosis.

Sensitivity was defined as the true positive rate whereby the test was the final cytologic diagnosis, Specificity as the true negative rate (proportion of actual negatives that are correctly identified as such), positive predictive value was defined as the number of true positive divided the number of positive calls (true positive and false positive), negative predictive value was defined as the number of true negative divided the number of negative calls (true negative and false negative). Diagnostic accuracy was defined as the ratio between the sum of true positive and true negative values divided by the total number of masses.

Technical success was defined as the capability of sampling the target lesion associated with the presence of a visible core, according to endosonographer's judgment, potentially useful for the final pathological analysis.

Adverse events were defined based on the criteria expressed by Cotton et al. [Cotton PB. Gastrointest Endosc 2010;71:446-54] Samples positive for malignancy were considered diagnostic for malignancy, while in patients with negative Ultrasound-guided fine-needle biopsy, surgical specimen evaluation, results of other diagnostic investigations and/or a clinical follow-up of at least 6 months were used to establish the definitive diagnosis.

Statistical Analysis The sample size was calculated based on the results of a previous study [Nakai Y H. Dig Dis Sci. 2014;59:1578-85] that showed that blood contamination of the specimen was lower with the stylet slow-pull technique as compared with the standard suction technique (25% vs 70%), with a consequent increase in the diagnostic accuracy. Based on these data we calculated for a difference of 25%, at a power of 80% and an alpha of 0.05 (two-sided test), a final sample size of 110 patients (55 patients in each group). Continuous variables will be reported as mean +/- standard deviation (SD) or as median with interquartile range. Categorical variables will be presented as numbers and percentage and will be compared either using the chi-square test (with Yates' correction when appropriate) or Fisher exact test.

Statistical was conducted using the Fisher's exact test for categorical variables and the Mann-Whitney U-test for continuous variables. Sensitivity, specificity, positive predictive value, negative predictive value, and overall diagnostic accuracy for each arm were investigated by comparing the results with the definitive diagnosis. Statistical tests were considered significant at a corresponding p value of <0.05. Data handling and analyses were done with SPSS 14.

Study Type

Interventional

Enrollment (Actual)

110

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Palermo, Italy, 90127
        • ARNAS Civico - Di Cristina - Benfratelli Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age >18years old
  • Solid pancreatic lesion on imaging MRI and/or CT-scan referred for tissue acquisition
  • Lesion can be visualized with EUS and needle puncturing can be technically feasible
  • Able to sign informed consent

Exclusion Criteria:

  • < 18 years-old
  • Cystic pancreatic lesions
  • Extra-pancreatic lesions or inaccessible/non-visualized lesions
  • Previous gastrectomy
  • International normalized ratio > 1.5
  • Impossibility to suspend anticoagulant therapy
  • Platelet count < 50.000 cells/cubic millimeter
  • Severe or unstable clinical conditions
  • Pregnancy
  • Inability to give informed consent
  • Refusal to participate to the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Stylet Slow-Pull Technique group
In patients randomized to the stylet slow-pull techniques an endoscopic ultrasound-guided fine needle biopsy of the pancreatic mass were made with a 20 Gauge needle (EchoTip ProCore 20G with ReCoil Stylet™, Cook Medical, Bloomington, IN, USA): 15 to-and-fro movements within the lesion were performed, with simultaneous minimal negative pressure provided by pulling the needle stylet slowly and continuously.
During endosonographic examination, the pancreatic mass was evaluated with color Doppler to avoid the involvement of vessels. The needle (20 Gauge, EchoTip ProCore 20G with ReCoil Stylet™, Cook Medical, Bloomington, IN, USA) was sharpened by withdrawing the stylet approximately 2 mm, and then was advanced into the lesion: 15 to-and-fro movements within the lesion were performed, with simultaneous minimal negative pressure provided by pulling the needle stylet slowly and continuously.
Other Names:
  • Endoscopic ultrasound-guided fine needle biopsy of pancreas
Active Comparator: Standard Suction Technique group
In patients randomized to the standard suction technique an endoscopic ultrasound-guided fine needle biopsy of the pancreatic mass were made with a 20 Gauge needle (EchoTip ProCore 20G with ReCoil Stylet™, Cook Medical, Bloomington, IN, USA): 15 to-and-fro movements within the lesion were performed with the use of a 10-mL suction syringe.
During endosonographic examination, the pancreatic mass was evaluated with color Doppler to avoid the involvement of vessels. The needle (20 Gauge, EchoTip ProCore 20G with ReCoil Stylet™, Cook Medical, Bloomington, IN, USA) was sharpened by withdrawing the stylet approximately 2 mm, and then was advanced into the lesion: 15 to-and-fro movements within the lesion were performed using a 10-mL suction syringe.
Other Names:
  • Endoscopic ultrasound-guided fine needle biopsy of pancreas

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Degree of blood contamination of samples after endoscopic ultrasound-guided fine needle biopsy of pancreatic mass
Time Frame: 7 days
Blood contamination of the specimen was considered significant (large amount of blood cells made pathological diagnosis difficult) or not-significant (no/few blood cells without influence on the pathological diagnosis) based on the pathologist evaluation of the formalin fixed and paraffin embedded (FFPE) tissue samples
7 days
Diagnostic accuracy of samples obtained after endoscopic ultrasound-guided fine needle biopsy of pancreatic mass
Time Frame: up to 6 months
Diagnostic accuracy was defined as the ratio between the sum of true positive and true negative values divided by the total number of masses. Sensitivity was defined as the true positive rate whereby the test was the final cytologic diagnosis. Specificity, positive predictive value (PPV), negative predictive value (NPV) were also evaluated.
up to 6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Technical success of the procedure after endoscopic ultrasound-guided fine needle biopsy of pancreatic mass
Time Frame: 5 minutes
Technical success was defined as the presence of a visible core, according to endosonographer's judgment, potentially useful for the final pathological analysis.
5 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Roberto Di Mitri, ARNAS Civico Di Cristina Benfratelli Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2017

Primary Completion (Actual)

May 31, 2018

Study Completion (Actual)

May 31, 2018

Study Registration Dates

First Submitted

February 16, 2019

First Submitted That Met QC Criteria

February 20, 2019

First Posted (Actual)

February 21, 2019

Study Record Updates

Last Update Posted (Actual)

February 26, 2019

Last Update Submitted That Met QC Criteria

February 22, 2019

Last Verified

February 1, 2019

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pancreatic Solid Lesions

Clinical Trials on Stylet slow-pull technique

3
Subscribe